These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 8730458)
41. [Study of recombinant human erythropoietin treatment on the anemia of predialysis patients]. Furukawa A; Numata A; Imagawa A; Kaifu Y; Sumikura T; Miyake H; Obayashi S; Nakazora H; Hirohata M; Miki S Nihon Jinzo Gakkai Shi; 1992 Jun; 34(6):693-700. PubMed ID: 1479709 [TBL] [Abstract][Full Text] [Related]
42. [Therapy of renal anemia with recombinant human erythropoietin]. Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487 [TBL] [Abstract][Full Text] [Related]
43. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U; Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476 [TBL] [Abstract][Full Text] [Related]
44. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study]. Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC; Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064 [TBL] [Abstract][Full Text] [Related]
45. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study. Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328 [TBL] [Abstract][Full Text] [Related]
46. Subcutaneous erythropoietin in the treatment of renal anaemia. Drinovec J; Varl J Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004 [TBL] [Abstract][Full Text] [Related]
47. Anemia of chronic renal failure: treatment with erythropoietin. Navarro M; Alonso A; Avilla JM; Espinosa L Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893 [TBL] [Abstract][Full Text] [Related]
48. A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group. Laupacis A Transplant Proc; 1991 Apr; 23(2):1825-6. PubMed ID: 2053167 [TBL] [Abstract][Full Text] [Related]
49. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? Besarab A; McCrea JB ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674 [No Abstract] [Full Text] [Related]
50. Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration. Raymond CB; Collins DM; Bernstein KN; Skwarchuk DE; Vercaigne LM Nephron Clin Pract; 2006; 102(3-4):c88-92. PubMed ID: 16282700 [TBL] [Abstract][Full Text] [Related]
51. Two years experience of daily self-administered subcutaneous erythropoietin. Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M Blood Purif; 1990; 8(5):268-71. PubMed ID: 2091686 [TBL] [Abstract][Full Text] [Related]
52. [Different response to human recombinant erythropoietin in patients undergoing hemodialysis treatment]. Petković N; Ristić S; Stosović M; Dukanović L Med Pregl; 2013; 66(3-4):130-7. PubMed ID: 23653990 [TBL] [Abstract][Full Text] [Related]
53. Recombinant human erythropoietin for the treatment of anemia in chronic myelogenous leukemia. Bourantas KL; Tsiara S; Makis A; Chaidos A; Christou L; Konstantinidou P; Kolios G; Seferiadis K Eur J Haematol; 1997 Oct; 59(4):263-5. PubMed ID: 9338625 [No Abstract] [Full Text] [Related]
54. Erythropoietin and cardiovascular risk. Allegra V; Martimbianco L; Mengozzi G; Vasile A Blood Purif; 1995; 13(6):301-13. PubMed ID: 8821194 [TBL] [Abstract][Full Text] [Related]
55. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948 [TBL] [Abstract][Full Text] [Related]
56. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients. Nephron; 1992; 61(4):399-403. PubMed ID: 1501735 [TBL] [Abstract][Full Text] [Related]
57. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin. Schaefer RM; Kuerner B; Zech M; Denninger G; Borneff C; Heidland A Int J Artif Organs; 1988 Jul; 11(4):249-54. PubMed ID: 3410565 [TBL] [Abstract][Full Text] [Related]
58. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach]. Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145 [TBL] [Abstract][Full Text] [Related]
59. Effect of human recombinant erythropoietin treatment on erythrocyte delta-aminolevulinic acid dehydratase in patients on maintenance hemodialysis. Djordjević VB; Pavlović D; Pejović M; Lecić N; Koraćević D; Djordjević V; Stefanović V Nephron; 1993; 65(3):497-8. PubMed ID: 8290015 [No Abstract] [Full Text] [Related]
60. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta. Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]